
    
      A phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety,
      tolerability, PK, and PD of IMR-687 (phosphodiesterase (PDE) 9 inhibitor) administered once
      daily (qd) for 36 weeks in 2 populations of adult subjects with Î²-thalassemia: Population 1
      (Transfusion Dependent Thalassemia (TDT) subjects) and Population 2 (Non-Transfusion
      Dependent Thalassemia (NTDT) subjects).
    
  